Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients

Table 2

Differences in miRNA expression in PTC patients with different clinicopathological features.

Clinicopathologic; features	miRNA-221		miRNA-222		miRNA-146b		miRNA-181		miRNA-21
	2^−ΔΔCt	𝑃	2^−ΔΔCt	𝑃	2^−ΔΔCt	𝑃	2^−ΔΔCt	𝑃	2^−ΔΔCt	𝑃
Sex
Male	9.03; (0.73–269.35)	0.694	7.56; (0.75–58.31)	0.739	129.37; (0.72–552.00)	0.425	5.58; (0.57–12.55)	0.579	10.86; (1.23−38.03)	0.461
Female	8.99; (0.68–212.90)		8.24; (0.04–168.94)		104.69; (1.28–2917.96)		3.15; (0.09–80.72)		7.70; (0.06−168.32)
Age
<45 years	8.82; (0.68–212.90)	0.693	7.55; (0.04–168.94)	0.137	103.97; (0.72–2917.96)	0.735	3.38; (0.49–80.72)	0.749	7.07; (1.23−168.32)	0.585
≥45 years	9.29; (0.73–269.35)		13.03; (0.81–58.31)		138.19; (2.36–1123.18)		2.95; (0.09–12.55)		8.32; (0.06−28.83)
Size
<2 cm	7.19; (0.73–212.90)	0.004	7.56; (0.75–168.94)	0.244	82.08; (0.72–2917.96)	0.088	2.99; (0.09–80.72)	0.008	6.96; (0.06−168.32)	0.143
≥2 cm	15.60; (0.68–269.35)		10.70; (0.04–58.31)		150.07; (1.28–1123.18)		5.58; (1.21–18.86)		11.24; (1.42−35.14)
TNM stage
I/II	8.41; (0.68–212.90)	0.041	7.30; (0.04–168.94)	0.004	92.70; (0.72–2917.96)	0.286	3.12; (0.49–80.72)	0.286	7.26; (1.23−168.32)	0.157
III/IV	21.44; (2.70–269.35)		28.51; (2.73–58.31)		183.96; (5.00–278.56)		4.80; (0.09–12.55)		15.05; (0.06−27.56)
LN metastasis
No	6.68; (0.73–212.90)	0.033	4.54; (0.75–22.92)	0.014	82.15; (0.72–2917.96)	0.250	2.36; (0.57–80.72)	0.103	7.17; (1.23−168.32)	0.423
Yes	14.43; (0.68–269.35)		11.82; (0.04–168.94)		129.37; (1.28–1123.18)		4.35; (0.09–18.86)		9.82; (0.06–28.83)
BRAF mutation
No	6.36; (0.68–269.35)	0.001	4.73; (0.04–168.94)	0.019	55.11; (0.72–2917.96)	0.003	2.46; (0.09–80.72)	0.005	6.81; (0.06–168.32)	0.104
Yes	15.29; (2.70–62.02)		11.82; (2.73–43.93)		182.19; (10.70–1123.18)		5.58; (2.08–18.86)		10.86; (1.44–28.83)
Heteromorphic nucleus
No	9.16; (0.68–269.35)	0.819	10.39; (0.04–168.94)	0.302	118.72; (0.72–2917.96)	0.240	3.38; (0.09–80.72)	0.797	8.32; (0.06–168.32)	0.548
Yes	8.82; (0.86–18.00)		6.13; (1.94–8.24)		49.69; (6.77–144.74)		3.12; (0.49-9.49)		5.46; (1.44-39.03)
Multicentricity
No	8.33; (0.73–212.90)	0.807	7.94; (0.75–168.94)	0.940	92.67; (0.72–2917.96)	0.807	3.26; (0.49–0.72)	0.866	9.00; (1.23–168.32)	0.275
Yes	10.01; (0.68–269.35)		7.63; (0.04–58.31)		118.72; (1.28–313.67)		3.23; (0.09–18.86)		7.07; (0.06–35.14)
AMES
Low	8.99; (0.68–212.90)	0.341	7.65; (0.04–168.94)	0.203	8	0.862	3.15; (0.09–80.72)	0.266	7.60; (0.06–168.32)	0.583
High	22.82; (0.73–269.35)		37.91; (1.67–58.31)		150.07; (2.36–278.56)		5.59; (0.57–12.55)		8.75; (1.30–27.40)
Thyroglobulin level
Low	7.67; (0.68–21.50)	0.225	12.23; (0.82–13.37)	0.626	205.95; (1.28–208.88)	0.427	2.46; (1.21–4.35)	0.993	17.55; (1.42–27.56)	0.407
Normal	8.17; (0.73–212.90)		7.65; (0.04–168.94)		103.26; (0.72–2917.96)		3.15; (0.09–80.72)		7.17; (0.06–168.32)
High	13.01; (1.14–269.35)		10.82; (0.81–58.31)		136.74; (6.75–1123.18)		3.44; (0.79–12.55)		8.89; (3.91–28.83)

The data are shown as median (range); 𝑃 value was determined by the Mann-Whitney U test.
TNM: tumor node metastasis; LN: lymph nodes; AMES: age, metastasis to distant sites, extrathyroidal invasion, and tumor size scoring system.